(Total Views: 338)
Posted On: 12/18/2017 12:57:52 PM
Post# of 30066
Quote:
The Company previously requested rare pediatric disease designation (RPDD) from the FDA for ESS in the treatment of Giant Congenital Melanocytic Nevus (GCMN), which was not accepted; Cutanogen intends to appeal that decision. The Company believes ESS has the potential to receive RPDD for ESS in the treatment of pediatric severe burns.
https://finance.yahoo.com/news/amarantus-prov...00483.html
I was suprised we didn't get it for GCMN, i would really thought we would get it for such a rare disease!
We still have another shot at goal though!
(6)
(0)
